Clinical Trials List
2023-06-01 - 2032-02-29
Phase III
Recruiting3
ICD-10C82.00
Follicular lymphoma grade I, unspecified site
ICD-10C82.09
Follicular lymphoma grade I, extranodal and solid organ sites
ICD-10C82.10
Follicular lymphoma grade II, unspecified site
ICD-10C82.19
Follicular lymphoma grade II, extranodal and solid organ sites
ICD-10C82.20
Follicular lymphoma grade III, unspecified, unspecified site
ICD-10C82.29
Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
ICD-10C82.30
Follicular lymphoma grade IIIa, unspecified site
ICD-10C82.39
Follicular lymphoma grade IIIa, extranodal and solid organ sites
ICD-10C82.40
Follicular lymphoma grade IIIb, unspecified site
ICD-10C82.49
Follicular lymphoma grade IIIb, extranodal and solid organ sites
ICD-10C82.50
Diffuse follicle center lymphoma, unspecified site
ICD-10C82.59
Diffuse follicle center lymphoma, extranodal and solid organ sites
ICD-10C82.60
Cutaneous follicle center lymphoma, unspecified site
ICD-10C82.69
Cutaneous follicle center lymphoma, extranodal and solid organ sites
ICD-10C82.80
Other types of follicular lymphoma, unspecified site
ICD-10C82.89
Other types of follicular lymphoma, extranodal and solid organ sites
ICD-10C82.90
Follicular lymphoma, unspecified, unspecified site
ICD-10C82.99
Follicular lymphoma, unspecified, extranodal and solid organ sites
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9202.00
Nodular lymphoma, unspecified site, extranodal solid organ sites
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Huey-En Tzeng Division of Hematology & Oncology
- Chieh-Lin Teng Division of Hematology & Oncology
- PO-WEI LIAO Division of Hematology & Oncology
- 滕傑林 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 田豐銘 Division of General Internal Medicine
- Chien-Chin Lin Division of Others -
- 施怡倫 Division of Radiology
- WEI-LI MA Division of Hematology & Oncology
- 劉高郎 Division of Radiology
- 李思慧 Division of Family Medicine
- - - Division of General Internal Medicine
- Tai-Chung Huang Division of General Internal Medicine
- Chieh-Lung Cheng Division of General Internal Medicine
- Shang-Ju Wu Division of General Internal Medicine
- HSIN-AN HOU Division of General Internal Medicine
- 柯紀綸 Division of Nuclear Medicine
- Ming-Che Kuo Division of Neurology
- CHENG-HONG TSAI Division of General Internal Medicine
- Wen-Chien Chou Division of Others -
- YAO CHI-YUAN Division of Others -
- 徐思淳 Division of Others
- Huai-Hsuan Huang Division of General Internal Medicine
- 范淞斌 Division of Neurology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 許獻文 Division of Hematology & Oncology
- 劉鴻霖 Division of Hematology & Oncology
- 邱玲榕 Division of Hematology & Oncology
- 廖碧涵 Division of Hematology & Oncology
- 林偉哲 Division of Hematology & Oncology
- Hong jie Chen Division of Hematology & Oncology
- 馬銘君 Division of Hematology & Oncology
- 劉婷婷 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12-18 participants
-
Global
108 participants
